Project overview
Reduced resilience, poor fitness, malnutrition, and emotional distress are major public health concerns, increasing adverse outcomes after cancer treatments, especially in advanced cancer patients undergoing cancer therapies (chemotherapy/radiotherapy/immunotherapy). Multimodal prehabilitation before surgery reduces postoperative complications, improves quality-of-life (QoL), fitness, and mitigates against co-morbidity. The underlying mechanisms that underpin these changes and contribute to variability in response to prehabilitation and surgical outcomes remain unknown.
The research will focus on enhanced resilience to cancer treatments through specialist prehabilitation interventions, interrogate muscle structure/function using body composition techniques and interrogate cancer immunology and redox biology status in association with tumour regression to improve long-term cancer and survival outcomes. Rapid clinical translational work of this kind represents a large clinical and research unmet need.
This project builds on more than 12 years of prehabilitation research clinical trial experience. These trials have all been led by the Southampton team, all contributing to an extensive and unique physiology, cancer/surgical outcomes, tumour and imaging biobank.
The project benefits from the full support of the internationally recognised, perioperative and prehabilitation medicine Southampton team. They will work with uniquely curated data and sample bioresource and expert clinical trials team that has delivered multimodal prehabilitation to >1500 cancer patients, including patients undergoing neoadjuvant/adjuvant/palliative cancer therapies in-hospital, in the community and virtually nationwide. World-class laboratory support and facilities are accessed by though collaborations with the cancer immunology (Al-Shamkhani/Beers labs) and redox biology (Feelisch lab) groups.
Together with collaborators from Southampton, the Royal Marsden, other BRCs nationally and charity partners, this project will refine current standard-of-care prehabilitation interventions, aimed at personalised intervention to further improve patient resilience, body composition and tumour outcomes. This project will produce essential pump-priming data to inform definitive trials.
The research will focus on enhanced resilience to cancer treatments through specialist prehabilitation interventions, interrogate muscle structure/function using body composition techniques and interrogate cancer immunology and redox biology status in association with tumour regression to improve long-term cancer and survival outcomes. Rapid clinical translational work of this kind represents a large clinical and research unmet need.
This project builds on more than 12 years of prehabilitation research clinical trial experience. These trials have all been led by the Southampton team, all contributing to an extensive and unique physiology, cancer/surgical outcomes, tumour and imaging biobank.
The project benefits from the full support of the internationally recognised, perioperative and prehabilitation medicine Southampton team. They will work with uniquely curated data and sample bioresource and expert clinical trials team that has delivered multimodal prehabilitation to >1500 cancer patients, including patients undergoing neoadjuvant/adjuvant/palliative cancer therapies in-hospital, in the community and virtually nationwide. World-class laboratory support and facilities are accessed by though collaborations with the cancer immunology (Al-Shamkhani/Beers labs) and redox biology (Feelisch lab) groups.
Together with collaborators from Southampton, the Royal Marsden, other BRCs nationally and charity partners, this project will refine current standard-of-care prehabilitation interventions, aimed at personalised intervention to further improve patient resilience, body composition and tumour outcomes. This project will produce essential pump-priming data to inform definitive trials.
